Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05765_nanopub.RAG0TxQrWKaCzwp_LZJt6dFiScYXHJNW0U-8_I4LgPLC4#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05765 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05765 label "ATX-201 [drugbank:DB05765]" assertion.
- drugbank:DB05765 seeAlso DB05765 assertion.
- drugbank:DB05765 description "ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their expected primary and exploratory objectives." assertion.
- drugbank:DB05765 identifier "drugbank:DB05765" assertion.
- drugbank:DB05765 title "ATX-201" assertion.
- drugbank:DB05765 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05765 drugbank_vocabulary:drugbank-id "DB05765" assertion.
- drugbank:DB05765 bio2rdf_vocabulary:x-identifiers.org DB05765 assertion.
- drugbank:DB05765 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05765" assertion.
- drugbank:DB05765 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05765 bio2rdf_vocabulary:identifier "DB05765" assertion.